Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana (Nasdaq: TLSA) reported that the last patient in its Phase 2a INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis has received a first dose. The randomized, double-blind, placebo-controlled study will enroll up to 48 patients across multiple U.S. sites, with topline data expected in late Q3/early Q4 2026 and a planned presentation at ACTRIMS/ECTRIMS in October 2026.
Tiziana Life Sciences (Nasdaq: TLSA) reported that Executive Chairman and founder Gabriele Cerrone, via Panetta Partners, purchased 15,000 common shares at $1.11 per share. This transaction increased his total holding to 44,772,230 shares, representing 34.89% of Tiziana's issued share capital.
Tiziana Life Sciences (Nasdaq: TLSA) will present at the Jefferies Global Healthcare Conference in New York City.
CEO Ivor Elrifi and COO/CFO Keeren Shah will give a corporate presentation on June 4, 2026, from 10:30–11:00 AM ET, covering recent clinical and corporate updates, followed by a Q&A with institutional investors.
Tiziana Life Sciences (Nasdaq: TLSA) has fully enrolled 48 patients in INFORM-MS, its randomized, double-blind, placebo-controlled Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
The 12-week study includes PET, MRI and biomarker assessments, followed by a six-month open-label extension. Topline data are expected in late Q3 2026 and will be presented at ACTRIMS/ECTRIMS in October 2026.
Tiziana (Nasdaq: TLSA) reported updated clinical data from its Expanded Access Program of intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis as of March 2026.
Foralumab remained well tolerated, with trends toward disability stabilization on EDSS and 64% of patients achieving clinically meaningful fatigue improvement on MFIS (≥4-point reduction), though results are not statistically significant.
Tiziana Life Sciences (Nasdaq: TLSA) reported initial Phase 2 PET imaging data for intranasal foralumab in Multiple System Atrophy (MSA).
In the first two MSA patients, PET scans showed up to ~35% reduction in SUV and ~24% reduction in SUVR in disease-relevant brain regions, suggesting reduced neuroinflammatory activity.
This is the third indication with observed PET inflammation reduction for intranasal foralumab, following non-active secondary progressive multiple sclerosis and moderate Alzheimer’s disease.
Tiziana Life Sciences (NASDAQ: TLSA) announced publication (April 16, 2026) of positive preclinical data on intranasal foralumab in a bioRxiv preprint. The mouse study showed reduced neuroinflammation, increased brain FoxP3+ IL-10+ Tregs, restored hippocampal neurogenesis, and improved short-term memory. Human observational data linked Long COVID neurological symptoms to lower circulating Tregs. The preprint is not yet peer-reviewed.
Tiziana Life Sciences (Nasdaq: TLSA) announced a late-breaking poster acceptance for its Phase 2a TILS-025 study of intranasal foralumab in Multiple System Atrophy (MSA) at the 7th World Parkinson Congress, May 24-27, 2026 in Phoenix.
The poster describes the open-label trial (NCT06868628) enrolling up to 10 MSA patients to assess microglial activation by TSPO PET and clinical scores over six months.
Tiziana Life Sciences (Nasdaq: TLSA) announced preclinical data showing intranasal anti-CD3 (foralumab) reversed key aspects of brain aging and improved cognition in an aging model.
Findings report reduced microglial activation, enhanced hippocampal neurogenesis, and lowered cellular senescence markers, supporting further clinical development in neurodegenerative indications.
Tiziana Life Sciences (Nasdaq: TLSA) reported biomarker results showing intranasal foralumab reduced PET-measured microglial activation and shifted CSF proteomics toward decreased inflammation and increased neuroprotection in na-SPMS patients with PIRA.
Findings from 10 patients (14 paired evaluations) showed significant PET m-GALP z-score reductions (p<0.05 at 3 months+), strong correlations between PET and CSF proteins (r up to 0.896 and -0.931, p<0.05), clinical stabilization/improvement, and no serious treatment-related adverse events. Phase 2a top-line data expected H1 2026.